Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance
- PMID: 23085775
- PMCID: PMC3543120
- DOI: 10.1093/jac/dks409
Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance
Abstract
Objectives: To determine whether pan-protease inhibitor (PI)-resistant virus populations are composed predominantly of viruses with resistance to all PIs or of diverse virus populations with resistance to different subsets of PIs.
Methods: We performed deep sequencing of plasma virus samples from nine patients with high-level genotypic and/or phenotypic resistance to all licensed PIs. The nine virus samples had a median of 12 PI resistance mutations by direct PCR Sanger sequencing.
Results: For each of the nine virus samples, deep sequencing showed that each of the individual viruses within a sample contained nearly all of the mutations detected by Sanger sequencing. Indeed, a median of 94.9% of deep sequence reads had each of the PI resistance mutations present as a single chromatographic peak in the Sanger sequence. A median of 5.0% of reads had all but one of the Sanger mutations that were not part of an electrophoretic mixture.
Conclusions: The collinearity of PI resistance mutations in the nine virus samples demonstrated that pan-PI-resistant viruses are able to replicate in vivo despite their highly mutated protease enzymes. We hypothesize that the marked collinearity of PI resistance mutations in pan-PI-resistant virus populations results from the unique requirements for multi-PI resistance and the extensive cross-resistance conferred by many of the accessory PI resistance mutations.
Similar articles
-
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.PLoS Med. 2007 Jan;4(1):e36. doi: 10.1371/journal.pmed.0040036. PLoS Med. 2007. PMID: 17227139 Free PMC article.
-
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.J Virol. 2009 Apr;83(7):3059-68. doi: 10.1128/JVI.02539-08. Epub 2009 Jan 28. J Virol. 2009. PMID: 19176623 Free PMC article.
-
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.AIDS. 2000 Jun 16;14(9):1203-10. doi: 10.1097/00002030-200006160-00018. AIDS. 2000. PMID: 10894285
-
Resistance to protease inhibitors.J HIV Ther. 2002 Nov;7(4):87-91. J HIV Ther. 2002. PMID: 12733606 Review.
-
Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro.Curr Pharm Des. 2004;10(32):4055-64. doi: 10.2174/1381612043382477. Curr Pharm Des. 2004. PMID: 15579087 Review.
Cited by
-
Highly Drug-Resistant HIV-1 Protease Mutant PRS17 Shows Enhanced Binding to Substrate Analogues.ACS Omega. 2019 May 31;4(5):8707-8719. doi: 10.1021/acsomega.9b00683. Epub 2019 May 17. ACS Omega. 2019. PMID: 31172041 Free PMC article.
-
Amino Acid Prevalence of HIV-1 pol Mutations by Direct Polymerase Chain Reaction and Single Genome Sequencing.AIDS Res Hum Retroviruses. 2019 Oct;35(10):924-929. doi: 10.1089/AID.2018.0289. Epub 2019 Aug 26. AIDS Res Hum Retroviruses. 2019. PMID: 31317771 Free PMC article.
-
Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning.J Chem Theory Comput. 2021 Apr 13;17(4):2054-2064. doi: 10.1021/acs.jctc.0c01244. Epub 2021 Mar 30. J Chem Theory Comput. 2021. PMID: 33783217 Free PMC article.
-
Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.Biochemistry. 2019 Sep 3;58(35):3711-3726. doi: 10.1021/acs.biochem.9b00446. Epub 2019 Aug 19. Biochemistry. 2019. PMID: 31386353 Free PMC article.
-
Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1.Antimicrob Agents Chemother. 2013 Sep;57(9):4290-4299. doi: 10.1128/AAC.00614-13. Epub 2013 Jun 24. Antimicrob Agents Chemother. 2013. PMID: 23796938 Free PMC article.
References
-
- Talbot A, Grant P, Taylor J, et al. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother. 2010;54:2473–9. doi:10.1128/AAC.00096-10. - DOI - PMC - PubMed
-
- Doherty KM, Nakka P, King BM, et al. A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes. BMC Bioinformatics. 2011;12:477. doi:10.1186/1471-2105-12-477. - DOI - PMC - PubMed
-
- Weinheimer S, Discotto L, Friborg J, et al. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother. 2005;49:3816–24. doi:10.1128/AAC.49.9.3816-3824.2005. - DOI - PMC - PubMed
-
- Wiesmann F, Vachta J, Ehret R, et al. The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors atazanavir and saquinavir: is there a clinical advantage? AIDS Res Ther. 2011;8:7. doi:10.1186/1742-6405-8-7. - DOI - PMC - PubMed
-
- Ziermann R, Limoli K, Das K, et al. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol. 2000;74:4414–9. doi:10.1128/JVI.74.9.4414-4419.2000. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
